Misplaced Pages

Petrelintide

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (August 2024)
Pharmaceutical compound
Petrelintide
Clinical data
Other namesZP8396
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Petrelintide (development name ZP8396) is an amylin analogue dosed once weekly, developed by Zealand Pharma for the treatment of type 2 diabetes and obesity. Preclinical data suggests it may be more effective in combination with semaglutide. In June 2024 the company announced results for a Phase 1b trial, which found 8.6 percent weight loss over 16 weeks.

References

  1. "ZP8396 (Amylin Analog)". Zealand Pharma A/S. Retrieved 11 March 2024.
  2. Skarbaliene, Jolanta; Baader-Pagler, Tamara; Eriksson, Per-Olof (2022). "213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats". Diabetes. 71 (Supplement_1). doi:10.2337/db22-213-OR.
  3. Olsen, Minna B.; HöVelmann, Ulrike; Griffin, Jon; Knudsen, Kim M.; Johansen, Thue; Kendall, David; Heise, Tim (20 June 2023). "92-LB: Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long-Acting Amylin Analog—A Single Ascending Dose Trial". Diabetes. 72 (Supplement_1). doi:10.2337/db23-92-LB.
  4. "Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions". BioSpace. Retrieved 1 November 2023.
  5. Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, MA; Henriksen, K. (1 December 2022). "Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models". Biomedicine & Pharmacotherapy. 156: 113842. doi:10.1016/j.biopha.2022.113842. ISSN 0753-3322.
  6. "Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide". BioSpace. 20 June 2024. Retrieved 21 August 2024.
Categories: